bluebird bio, Inc. (NASDAQ:BLUE – Get Free Report) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 49,370,000 shares, a growth of 20.0% from the August 15th total of 41,140,000 shares. Based on an average daily trading volume, of 7,240,000 shares, the days-to-cover ratio is presently 6.8 days.
bluebird bio Trading Up 5.5 %
bluebird bio stock traded up $0.03 during midday trading on Friday, reaching $0.61. The stock had a trading volume of 6,739,937 shares, compared to its average volume of 7,752,763. The company has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $1.02. The company has a market capitalization of $66.24 million, a P/E ratio of -0.82 and a beta of 0.75. bluebird bio has a 12 month low of $0.52 and a 12 month high of $5.53.
Hedge Funds Weigh In On bluebird bio
Institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its stake in bluebird bio by 144.7% during the 4th quarter. BNP Paribas Financial Markets now owns 524,963 shares of the biotechnology company’s stock valued at $724,000 after purchasing an additional 310,461 shares during the last quarter. Summit X LLC grew its holdings in bluebird bio by 10.2% during the fourth quarter. Summit X LLC now owns 178,952 shares of the biotechnology company’s stock worth $247,000 after buying an additional 16,584 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in bluebird bio in the 4th quarter valued at $37,000. Weiss Asset Management LP bought a new position in bluebird bio during the 4th quarter valued at $1,035,000. Finally, Monashee Investment Management LLC purchased a new position in bluebird bio during the 4th quarter worth $690,000. 87.43% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Read Our Latest Research Report on bluebird bio
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
Read More
- Five stocks we like better than bluebird bio
- Ride Out The Recession With These Dividend Kings
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.